Rigetti shares have been fighting for support at the $7.50 level for the last two weeks. That price level has held ...

Bill Strazzullo, Bell Curve Trading chief market strategist, said in a latest program on CNBC that the market rally that ...

IonQ faces market headwinds with high beta vulnerability, unsustainable valuations, and limited cash runway despite revenue ...

During a recent interview on CNBC, IonQ's CEO proclaimed that the company is the "800-pound gorilla" in the quantum computing ...

Batoclimab receives Orphan Drug Designation in Japan, advancing treatment for active Thyroid Eye Disease (TED). Batoclimab, subcutaneous formulation, offers the potential for at-home administration, ...

Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degeneration (AMD), today announced that ...

In this article, we are going to take a look at where IonQ, Inc. (NYSE:IONQ) stands against the other stocks. Wall Street’s main indices suffered a bloodbath on Thursday as overall investor ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

ID Quantique’s renowned team, technology, and products to join IonQ portfolio With addition of nearly 300 quantum networking patents from ID Quantique, issued and pending quantum patents IonQ controls ...

Jordan Shapiro; Vice President of Financial Planning and Analysis and Head of Investor Relations; IONQ Inc Peter Chapman; President, Chief Executive Officer, Director; IONQ Inc Niccolo de Masi ...

Jordan Shapiro; Vice President of Financial Planning and Analysis and Head of Investor Relations; IONQ Inc Peter Chapman; President, Chief Executive Officer, Director; IONQ Inc Niccolo de Masi; ...